R-PHARM US Expands its Oncology Asset Portfolio with the Exclusive License and Distribution Rights to episil® in the United States
21 avr. 2016 08h00 HE
|
R-PHARM US, LLC
PRINCETON, N.J., April 21, 2016 (GLOBE NEWSWIRE) -- R-PHARM US today announced it has obtained the exclusive license and distribution rights to commercialize episil® oral liquid in the U.S....
R-PHARM Acquires IXEMPRA(R) (ixabepilone) From Bristol-Myers Squibb and Launches U.S. Commercial Operations
17 août 2015 08h30 HE
|
R-PHARM US, LLC
PRINCETON, N.J., Aug. 17, 2015 (GLOBE NEWSWIRE) -- R-PHARM US announces the acquisition of IXEMPRA (ixabepilone) from Bristol-Myers Squibb (NYSE:BMY). IXEMPRA received marketing approval from the U.S....